Topics

Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience.

08:00 EDT 28th October 2019 | BioPortfolio

Summary of "Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience."

The value of a high-risk surveillance program for mutation carriers and women at high familial breast cancer risk has not been extensively studied. A Breast and Ovarian Cancer Risk Management Clinic (BOCRMC) was established at the Royal Melbourne Hospital in 2010 to provide multimodality screening and risk management strategies for this group of women. The aims of this study were to evaluate the program and describe breast cancer diagnoses for BRCA1, BRCA2, and other germline mutation carriers as well as high-risk noncarriers attending the BOCRMC.

Affiliation

Journal Details

This article was published in the following journal.

Name: Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Pages:

Links

DeepDyve research library

PubMed Articles [45583 Associated PubMed Articles listed on BioPortfolio]

What attitude to women at high risk of breast cancer?

In France, breast cancer is the most common cancer among women and the leading cause of cancer deaths. Identifying women with a "high" or "very high" breast cancer risk, according the terminology of t...

Screening Guidelines Update for Average-Risk and High-Risk Women.

The purpose of this study is to describe screening updates for women with average and high risk for breast cancer, compare different screening strategies, and describe new approaches in risk predictio...

Breast Cancer Screening Practices for High-Risk Women: A Cross-Sectional Survey of Primary Care Providers.

Little literature exists on primary care providers' knowledge and preferences toward breast cancer screening for high-risk women. A cross-sectional web-based survey of primary care providers in Minne...

Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.

Breast cancer is the most common nonskin cancer among women in the United States and the second leading cause of cancer death. The median age at diagnosis is 62 years, and an estimated 1 in 8 women wi...

Considerations when using breast cancer risk models for women with negative BRCA1/BRCA2 mutation results.

The performance of breast cancer risk models for women with a family history but negative BRCA1 and/or BRCA2 mutation test results is uncertain. We calculated the cumulative 10-year invasive breast ca...

Clinical Trials [33326 Associated Clinical Trials listed on BioPortfolio]

Specialist Recommendation on FBC (Familial Breast Cancer) Chemoprevention Prescribing

Some women are more likely to get breast cancer as it runs in their family, they are at risk of familial breast cancer. There are medications, called chemoprevention, which may lower their...

Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women

RATIONALE: Studying mammograms for breast density changes over time may help doctors predict breast cancer risk. PURPOSE: This natural history study is looking at changes in breast densit...

Phase IIb Trial of G-2535 (Unconjugated Isoflavones-100) in Women at High Risk for Breast Cancer

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of genistein may prevent breast cancer in women at high risk for breast...

Comparison of Genes in Healthy Women, Women at High Risk for Breast Cancer, and Women With Breast Cancer

RATIONALE: Genetic testing for specific genes that are associated with estrogen may help identify patients who are at greatest risk for developing breast cancer. PURPOSE: This clinical tr...

Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial

RATIONALE: Gathering information about the frequency and intensity of hot flashes in patients with breast cancer and in patients who have a high risk of developing breast cancer may help d...

Medical and Biotech [MESH] Definitions

A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

A hereditary disease characterized by multiple ectodermal, mesodermal, and endodermal nevoid and neoplastic anomalies. Facial trichilemmomas and papillomatous papules of the oral mucosa are the most characteristic lesions. Individuals with this syndrome have a high risk of BREAST CANCER; THYROID CANCER; and ENDOMETRIAL CANCER. This syndrome is associated with mutations in the gene for PTEN PHOSPHATASE.

Autosomal dominant HEREDITARY CANCER SYNDROME in which a mutation most often in either BRCA1 or BRCA2 is associated with a significantly increased risk for breast and ovarian cancers.

Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.

Quick Search


DeepDyve research library

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Searches Linking to this Article